Home Ingredients Pyritinol (Pyrithioxine / Encephabol)
CognitiveAnti-InflammatoryJoint Health

Pyritinol (Pyrithioxine / Encephabol)

Synthetic — disulfide-linked pyridoxine dimer
Evidence Level
Limited
3 Clinical Trials
6 Documented Benefits
2/5 Evidence Score

Pyritinol (also called pyrithioxine, marketed as Encephabol®) is a compound consisting of two vitamin B6 (pyridoxine) molecules linked by a disulfide bridge. Developed by Merck Laboratories in 1961, it's approved in several European countries (Austria, Germany, France, Italy, Portugal, Greece) for chronically impaired brain function in dementia and craniocerebral trauma sequelae. France additionally approves pyritinol as a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. A 12-week trial in 156 inpatients with senile dementia (Alzheimer type and multi-infarct) showed significant cognitive improvements at 600 mg/day. The honest framing: a European prescription drug with reasonable evidence for cognitive support in dementia syndromes and unique anti-inflammatory DMARD effects in rheumatoid arthritis; sold as a nootropic supplement in the US since the early 1990s but not FDA-approved. Approach with realistic expectations: this is a pharmaceutical-grade compound with specific therapeutic indications, not a casual nootropic.

Studied Dose Dementia (European Rx protocol): 200 mg hydrochloride three times daily (600 mg/day). Rheumatoid arthritis (France DMARD): 200-600 mg/day. Nootropic use: 200-600 mg/day split in 2-3 doses. Prescription required in EU; not FDA-approved in the US.
Active Compound Pyritinol (pyrithioxine, pyridoxine disulfide; chemical: 3,3'-(disulfanediylbis(methylene))bis(5-(hydroxymethyl)-2-methylpyridin-4-ol)) — two pyridoxine (B6) molecules with disulfide bridge

Benefits

Senile dementia cognitive support

A 12-week double-blind randomized trial in 156 inpatients with mild-to-moderate dementia (Alzheimer type or multi-infarct) at 600 mg/day showed significant improvements over placebo on cognitive performance tests, clinical global impression, and EEG measures of vigilance. Foundational evidence supporting European regulatory approvals.

Supported by Trial 1, Trial 2

Sustained long-term cognitive benefit

A long-term double-blind crossover study in 26 dementia patients with regional cerebral blood flow measurements showed pyritinol's beneficial cognitive effects sustained during 1-year follow-up. Limited by small sample but supports durability of effects observed in shorter trials.

Supported by Trial 3

Rheumatoid arthritis (DMARD approval)

France approves pyritinol as a disease-modifying antirheumatic drug for rheumatoid arthritis. A European multicenter study compared pyritinol with auranofin (gold therapy) and found comparable efficacy. Mechanism involves disulfide bridge SH-group anti-inflammatory effects — distinguishes pyritinol from typical nootropics.

Supported by Trial 2

Pediatric learning disabilities (European approval)

Approved in Germany and other European countries for pediatric learning disabilities, developmental dysphasia, postnatal hypoxia, and other pediatric cognitive disorders. Older studies showed effects on behavior and intellectual functioning in learning-disabled children. Older but supportive evidence base.

Supported by Trial 2

Cerebral metabolism enhancement

Pyritinol HCl improves cerebral blood flow and oxidative metabolism in patients with dementia. Mechanism for cognitive improvements via enhanced cerebral oxygen and glucose utilization — pharmacologically classified among cerebral metabolic enhancers for dementia treatment.

Supported by Trial 2, Trial 3

Hangover prevention (historical evidence)

An older double-blind comparison versus placebo showed pyritinol benefit in preventing alcohol-induced hangover symptoms. Limited modern replication but interesting historical use case for acute alcohol-induced cognitive and somatic symptoms.

Supported by Trial 3, Trial 2

Mechanism of action

1

Vitamin B6 (pyridoxine) delivery via disulfide cleavage

In vivo, disulfide bridge cleaves to release two molecules of pyridoxine (vitamin B6) — providing B6 substrate for amino acid metabolism, neurotransmitter synthesis (GABA, dopamine, serotonin via PLP coenzyme), and other B6-dependent functions. Mechanism for general neuroprotection.

2

BBB penetration via disulfide structure

Crosses BBB much more readily than pyridoxine itself due to disulfide structure providing lipophilicity. Accumulates in gray matter regions including hippocampus, cerebral nuclei, cerebellum, cortex. Mechanism for CNS effects beyond simple B6 supplementation.

3

Antioxidant activity via SH groups

Disulfide bridge can be reduced to two SH groups, providing antioxidant activity. Pyritinol shown to scavenge hydroxyl radicals. Mechanism for neuroprotection in ischemia and aging-related oxidative stress.

4

Cholinergic enhancement (without direct receptor binding)

Pyritinol enhances acetylcholine release without directly interacting with cholinergic receptors. Mechanism more complex than typical AChE inhibitors — involves membrane fluidity and lipid solubility effects. Mechanism for cognitive effects in dementia.

5

Anti-inflammatory effects

Pyritinol has anti-inflammatory effects relevant to RA approval — likely via SH-group effects on inflammatory mediators and neutrophil function modulation (Elferink & de Koster 1993). Distinguishes pyritinol from typical nootropics with documented systemic anti-inflammatory properties.

6

Plasma viscosity reduction and cerebral blood flow

Reduces plasma viscosity and improves cerebral blood flow. Mechanism for cognitive effects in vascular dementia and post-stroke contexts. Hoyer 1977 demonstrated cerebral metabolic effects in dementia patients.

Clinical trials

1
Fischhof 1992 — Pyritinol in SDAT/MID Pivotal RCT
PubMed

Double-blind randomized placebo-controlled trial (Fischhof PK, Saletu B, Rüther E, Litschauer G, Möslinger-Gehmayr R, Herrmann WM 1992, Pharmacopsychiatry 25(6):205-209, doi:10.1055/s-2007-1014434, PMID 1475039).

183 inpatients screened, 164 met inclusion criteria, 156 completed trial. Senile Dementia of Alzheimer Type (SDAT) and Multi-Infarct Dementia (MID) of mild-moderate degree. Allocation by Hachinski Ischemic Score, CT scans, EEG. 12-week double-blind treatment phase: pyritinol 200 mg dihydrochloride-monohydrate 3x daily (600 mg/day) vs placebo. Confirmatory statistics included CGI item 2, Short Cognitive Performance Test, Sandoz Clinical Assessment Geriatric scale 'cognitive disturbances' factor.

Pyritinol STATISTICALLY SIGNIFICANTLY SUPERIOR to placebo on ALL 3 TARGET VARIABLES. Clinical relevance underlined by descriptive variables and convergence at different observation levels. EEG MAPPING: pyritinol DECREASED slow activity, INCREASED fast alpha and beta — reflecting improved vigilance. Foundational positive RCT supporting European regulatory approvals for chronically impaired brain function. One of more rigorous racetam-class dementia trials.

2
Lemmel 1993 — Pyritinol vs Auranofin in Rheumatoid Arthritis
PubMed

European Multicenter Study Group RCT (Lemmel EM 1993, Br J Rheumatol 32(5):375-382, doi:10.1093/rheumatology/32.5.375).

Patients with rheumatoid arthritis randomized to pyritinol or auranofin (oral gold). Standard RA clinical and laboratory assessments.

Pyritinol showed COMPARABLE EFFICACY to auranofin (oral gold therapy) in rheumatoid arthritis. Foundational evidence supporting French regulatory approval as disease-modifying antirheumatic drug (DMARD). Distinguishes pyritinol from pure cognitive enhancers — has documented systemic anti-inflammatory and disease-modifying properties. Mechanism via SH-group anti-inflammatory effects.

3
Hindmarch 1990 — Pyritinol Long-term in SDAT Cross-over
PubMed

Double-blind cross-over trial (Hindmarch I, Coleston DM, Kerr JS 1990).

26 patients with clinical diagnosis of Senile Dementia of Alzheimer's type (SDAT). Randomly assigned in double-blind cross-over trial pyritinol vs placebo. Long-term follow-up 1 year. Psychiatric/neurological exam, psychometric testing, regional cerebral blood flow.

Pyritinol had BENEFICIAL EFFECT on cognitive performance SUSTAINED during long-term follow-up of 1 year. Memory performance improvement on battery of 7 tests with repeated 300 mg daily doses. Limited by small sample but important for demonstrating durability of effects. Supports clinical use for chronic dementia indications where sustained benefit matters.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; long-term clinical use in Europe supports safety profile.
Mild GI upset (nausea, abdominal discomfort).
Skin reactions (rash, pruritus) — more frequent than other racetams.
Headache.
RARE BUT SERIOUS: hepatic injury, taste disturbances, pancreatitis, lupus-like syndrome reported with chronic use.
Pregnancy/lactation: avoid (insufficient data despite B6 origin).
Renal impairment: caution.
Long-term safety: moderate European clinical use data.

Important Drug interactions

Levodopa: theoretical reduction of efficacy (B6 effect on peripheral decarboxylation — particularly relevant when not combined with carbidopa).
Penicillamine: theoretical interactions in rheumatoid arthritis combination therapy.
Other DMARDs (gold, methotrexate): combination not standard but possible.
Anticoagulants: limited interaction data.
Most medications: compatible at typical doses.
B6-related: monitor in patients with vitamin B6-related conditions.

More Cognitive Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Frequently asked questions about Pyritinol (Pyrithioxine / Encephabol)

What is Pyritinol (Pyrithioxine / Encephabol)?

Pyritinol (also called pyrithioxine, marketed as Encephabol®) is a compound consisting of two vitamin B6 (pyridoxine) molecules linked by a disulfide bridge.

What does Pyritinol (Pyrithioxine / Encephabol) do?

In vivo, disulfide bridge cleaves to release two molecules of pyridoxine (vitamin B6) — providing B6 substrate for amino acid metabolism, neurotransmitter synthesis (GABA, dopamine, serotonin via PLP coenzyme), and other B6-dependent functions. In clinical research, Pyritinol (Pyrithioxine / Encephabol) has been studied for senile dementia cognitive support, sustained long-term cognitive benefit, rheumatoid arthritis (dmard approval).

Who should take Pyritinol (Pyrithioxine / Encephabol)?

Pyritinol (Pyrithioxine / Encephabol) may be most relevant for people interested in cognitive, anti-inflammatory, joint health. It has been clinically studied for senile dementia cognitive support, sustained long-term cognitive benefit, rheumatoid arthritis (dmard approval). As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Pyritinol (Pyrithioxine / Encephabol) take to work?

Most clinical trial effects appear over weeks of consistent use; individual response varies. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Pyritinol (Pyrithioxine / Encephabol)?

For cognitive goals, Pyritinol (Pyrithioxine / Encephabol) is typically taken in the morning with breakfast for sustained daytime effects. Avoid late-day dosing if it affects your sleep. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Pyritinol (Pyrithioxine / Encephabol) worth taking?

Pyritinol (Pyrithioxine / Encephabol) has limited clinical evidence (Evidence Level 2/5 on NutraSmarts) — preliminary research suggests potential benefit, but more rigorous trials are needed. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Pyritinol (Pyrithioxine / Encephabol) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Pyritinol (Pyrithioxine / Encephabol)?

The clinically studied dose for Pyritinol (Pyrithioxine / Encephabol) is Dementia (European Rx protocol): 200 mg hydrochloride three times daily (600 mg/day). Rheumatoid arthritis (France DMARD): 200-600 mg/day. Nootropic use: 200-600 mg/day split in 2-3 doses. Prescription required in EU; not FDA-approved in the US.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Pyritinol (Pyrithioxine / Encephabol) used for?

Pyritinol (Pyrithioxine / Encephabol) is studied for senile dementia cognitive support, sustained long-term cognitive benefit, rheumatoid arthritis (dmard approval). A 12-week double-blind randomized trial in 156 inpatients with mild-to-moderate dementia (Alzheimer type or multi-infarct) at 600 mg/day showed significant improvements over placebo on cognitive performance tests, clinical global impression, and EEG …